Actively Recruiting
EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer
Led by Centre Georges Francois Leclerc · Updated on 2026-04-03
613
Participants Needed
6
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying genetic factors linked to early-onset cancer, focusing on patients with either inherited or spontaneous genetic alterations that may increase cancer risk. This study aims to evaluate a new genetic testing method called high-throughput exome sequencing (SHD-E) after standard gene panel tests fail to identify a genetic cause. The goal is to see if SHD-E can find additional genetic changes that contribute to cancer predisposition in patients diagnosed at a young age. Participants will undergo one genetic consultation and provide a blood sample for analysis. This approach is being assessed for patients diagnosed with cancer before age 40 (or before age 30 for breast cancer) who had negative results from routine gene panel tests. The study may also include tumor samples and, when necessary, testing of parents or affected relatives to support genetic analysis. During the study, participants will have their genetic mutations evaluated to identify new cancer risk factors. The study involves reviewing the genetic data collected from blood tests and possibly tumor samples. Participants must consent to join and be affiliated with a social security scheme. The primary outcome measured is the identification of genetic mutations that may explain cancer predisposition in these early-onset cases.
CONDITIONS
Brief Title
EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient is a minor or adult
- Has histological or cytological evidence of a malignant tumor diagnosis
- Cancer diagnosis before age 40, or before age 30 for breast cancer
- No anomaly found on routine oncogenetic gene panel test related to cancer predisposition
- Affiliated with a social security scheme
- Signed informed consent for the EXTRICAN study
- Availability of a tumor sample if secondary studies are needed
- Availability of both parents if trio genetic analysis is needed, or approval if parents are unavailable
- Availability of affected relatives if needed, or approval if relatives are unavailable
You will not qualify if you...
- Patient refuses to participate
- Psychiatric illness or condition affecting understanding or ability to participate
- Under guardianship, curatorship, or judicial protection
- Pregnant woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to several weeks depending on analysis time
Participants undergo a genetic consultation and a blood test to identify genetic predisposition factors for early-onset cancer after a negative routine gene panel test.
1 visit (in-person) for consultation and blood sample collection
Duration - Up to several years until study completion
Participants are observed for outcomes related to the genetic analysis over time.
Follow-up visits may occur depending on individual needs
Trial Site Locations
Total: 6 locations
1
CHRU Jean Minjoz
Besançon, France
Not Yet Recruiting
2
Centre Georges-François Leclerc
Dijon, France, 21000
Actively Recruiting
3
CHU de Dijon
Dijon, France
Not Yet Recruiting
4
CHU de Reims
Reims, France
Not Yet Recruiting
5
Polyclinique de Courlancy
Reims, France
Not Yet Recruiting
6
CH de Troyes
Troyes, France
Not Yet Recruiting
Research Team
S
Sophie NAMBOT, Dr
E
Emilie REDERSTORFF
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here